par Epigenomics AG (isin : DE000A0BVT96)
EQS-Adhoc: Epigenomics AG: Negotiations on the Acquisitions of Almost All Assets
EQS-Ad-hoc: Epigenomics AG / Key word(s): Miscellaneous
Epigenomics AG: Negotiations on the Acquisitions of Almost All Assets
12-Jun-2023 / 10:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Negotiations on the Acquisitions of Almost All Assets
Berlin, Germany, June 12, 2023 – Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) is in well advanced negotiations with an US based strategic investor (“Acquiror”) on the acquisition of almost all assets of the Company. Binding agreements have not yet been concluded, so negotiations could still fail. The assets, which are part of the agreement, will upon successful completion of the negotiations comprise in any case all patents and other intellectual property rights relating to Epi proColon and Epi proColon “NextGen” as well as all blood samples owned by the Company. The current state of negotiations envisages a purchase price of just over US$ 11.5 million, comprising payments in cash in an aggregate amount of US$ 1,500,000, which the Acquiror has to pay at closing and in December 2023, milestone payments relating to Epi proColon and Epi proColon “NextGen” as well as shares in the Acquiror. In addition, the current state of negotiations includes royalties and earn-out payments that the Company would receive in the event of commercialization of Epi proColon “NextGen”.
Contact:
Company
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com
Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com
Note on forward-looking statements
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
End of Inside Information
12-Jun-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Epigenomics AG |
| Geneststraße 5 | |
| 10829 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A32VN83 |
| WKN: | A32VN8 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1654515 |
| End of Announcement | EQS News Service |
1654515 12-Jun-2023 CET/CEST